Sinopharm Modern announced it will acquire a 51% stake in Sinopharm Group Guorui Pharmaceutical for 406 million yuan in cash. The counterparties are Sinopharm Group, Sinopharm Holdings, and Sinopharm Group Medicine. Upon completion, Guorui Pharmaceutical will become a controlled subsidiary of Sinopharm Modern, aiming to eliminate horizontal competition and enrich its product pipeline in areas such as the nervous system and anti-infection. This transaction constitutes a related-party transaction but does not constitute a major asset restructuring, and does not require submission to the shareholders' meeting for review.
Sinopharm Group Co LtdSinopharm Group is a counterparty selling its stake in Guorui, but the impact on Sinopharm Group itself is not detailed.
Sinopharm Modern acquires 51% of Guorui, making it a controlled subsidiary, which is a positive M&A event for the acquirer.
